Ovid Therapeutics (OVID) Receives $22.33 Consensus PT from Brokerages

Ovid Therapeutics (NASDAQ:OVID) has received an average rating of “Buy” from the seven brokerages that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $22.33.

OVID has been the subject of several research reports. Cowen restated a “buy” rating on shares of Ovid Therapeutics in a report on Sunday, April 1st. Piper Jaffray initiated coverage on shares of Ovid Therapeutics in a report on Friday, March 9th. They issued an “overweight” rating and a $20.00 price objective for the company. Zacks Investment Research lowered shares of Ovid Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, April 5th. Finally, ValuEngine upgraded shares of Ovid Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, December 31st.

How to Become a New Pot Stock Millionaire

NASDAQ OVID traded up $0.11 during trading on Tuesday, hitting $9.07. The company had a trading volume of 38,768 shares, compared to its average volume of 171,002. Ovid Therapeutics has a one year low of $5.28 and a one year high of $15.93. The firm has a market capitalization of $220.58 and a PE ratio of -2.71.



Ovid Therapeutics (NASDAQ:OVID) last issued its quarterly earnings data on Thursday, March 29th. The company reported ($0.45) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.06). research analysts expect that Ovid Therapeutics will post -2.19 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of OVID. Tekla Capital Management LLC grew its position in shares of Ovid Therapeutics by 229.7% in the 4th quarter. Tekla Capital Management LLC now owns 535,824 shares of the company’s stock worth $5,289,000 after buying an additional 373,287 shares during the period. Vanguard Group Inc. purchased a new stake in shares of Ovid Therapeutics in the 2nd quarter worth about $1,042,000. Northern Trust Corp purchased a new stake in shares of Ovid Therapeutics in the 2nd quarter worth about $604,000. State Street Corp purchased a new stake in shares of Ovid Therapeutics in the 2nd quarter worth about $520,000. Finally, Granite Point Capital Management L.P. purchased a new stake in shares of Ovid Therapeutics in the 4th quarter worth about $148,000. Institutional investors and hedge funds own 31.79% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Ovid Therapeutics (OVID) Receives $22.33 Consensus PT from Brokerages” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://stocknewstimes.com/2018/04/22/ovid-therapeutics-ovid-receives-22-33-consensus-pt-from-brokerages.html.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate that is in Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome, as well as in preclinical development stage for pediatrics with angelman syndrome.

Analyst Recommendations for Ovid Therapeutics (NASDAQ:OVID)

Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply